Rome, Italy

Angelo Peschiaroli

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • New York, NY (US) (2012)
  • Rome, IT (2011 - 2014)

Company Filing History:


Years Active: 2011-2014

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Angelo Peschiaroli

Introduction

Angelo Peschiaroli is a notable inventor based in Rome, Italy. He has made significant contributions to the field of biochemistry, particularly in the development of USP47 inhibitors. With a total of 4 patents to his name, Peschiaroli's work has the potential to impact therapeutic approaches in medicine.

Latest Patents

One of Peschiaroli's latest patents focuses on USP47 (ubiquitin specific protease 47) inhibitors and methods to induce apoptosis or cell death in target cells. This invention outlines methods and kits designed to screen for agents that can induce apoptosis. Additionally, it includes assays for screening compounds capable of acting as USP47 inhibitors. This innovative approach could lead to advancements in cancer treatment and other diseases where apoptosis plays a critical role.

Career Highlights

Peschiaroli is affiliated with New York University, where he continues to engage in groundbreaking research. His work has garnered attention in the scientific community, contributing to the understanding of cellular processes and potential therapeutic interventions.

Collaborations

Throughout his career, Peschiaroli has collaborated with esteemed colleagues such as Michele Pagano and Jeffrey R Skaar. These partnerships have further enriched his research and expanded the impact of his inventions.

Conclusion

Angelo Peschiaroli's contributions to the field of biochemistry through his patents on USP47 inhibitors highlight his innovative spirit and dedication to advancing medical science. His work not only showcases his expertise but also holds promise for future therapeutic developments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…